New 5,500 square meter facility will be located in Al Ain
New 5,500 square meter facility will be located in Al Ain
Mubadala Healthcare, a business unit of Mubadala Development Company (Mubadala), today announced plans to expand the existing services of Imperial College London Diabetes Centre (ICLDC) through the establishment of a second facility in Al Ain. This new Centre will provide world-class medical care for local residents in Al Ain and the surrounding region from the middle of next year.
The first Imperial College London Diabetes Centre facility opened in Abu Dhabi in 2006, following an agreement between Mubadala and Imperial College London to collaborate in the fields of healthcare, education and research. It was one of the first facilities to be established by Mubadala as part of its strategy to stimulate the development of a robust private healthcare infrastructure in the region.
The Centre is founded on the four pillars of treatment, training, public health and research, and provides the highest level of specialized and comprehensive patient care – from first diagnosis to the management of all the complications associated with diabetes. The expansion of services into Al Ain will be an extension of the same model of care.
The International Diabetes Federation has estimated that 18.7% of the UAE population is living with Diabetes and according to the Centre’s figures, an average of 15% of their patients reside outside Abu Dhabi in Al Ain.
“It is testament to the excellent work carried out at the Centre over the past four years that we are now able to replicate the same model of care for patients living outside the capital,” said Suhail Mahmood Al Ansari, Associate Director of Mubadala Healthcare and Chairman of ICLDC. “I am delighted to build upon our partnership with Imperial College London with a second facility and improve access to world-class healthcare in the region.”
In its first four years of operation, Imperial College London Diabetes Centre has achieved tremendous operational success with more than 27,000 registered patients, 80,000 one-to-one consultations conducted by the Centre’s specialist public health team, and an award-winning public health awareness campaign, “Diabetes. Knowledge. Action” that has reached out to countless others across the Emirates.
“This new facility will allow us to become an integral part of the Al Ain community” said Dr Maha Barakat, Medical and Research Director, Imperial College London Diabetes Centre. “Improved local access to our services will make it easier for patients to receive treatment, prevent the complications associated with diabetes, and ultimately live healthier lives.”
Mubadala Development Company (Mubadala) is a catalyst for the economic diversification of Abu Dhabi. Established and owned by the Government of Abu Dhabi, the company’s strategy is built on the management of partnerships and long-term, capital-intensive investments that deliver strong financial returns and tangible social benefits for the Emirate of Abu Dhabi, and contribute to the growth and diversification of its economy.
Mubadala brings together and manages a multi-billion dollar portfolio of local, regional, and international investments and partners with leading global organizations to operate businesses across a wide range of industry sectors including aerospace, energy, healthcare, industry, information communications and technology, infrastructure, real estate and hospitality. For more information about Mubadala please visit http://www.mubadala.ae
As part of Mubadala Development Company’s vision to act as a catalyst for economic development and build a prosperous future for the people of Abu Dhabi, Mubadala Healthcare is playing an instrumental role in the creation of a thriving healthcare sector for the Emirate.
By establishing partnerships with renowned international medical institutions, we are actively investing to develop healthcare services that provide patients with world-class treatment in their home country.
Mubadala Healthcare’s investment focus currently includes patient care delivery and ancillary services. We evaluate potential projects both on their likely commercial returns as well as on their socio-economic impact. Our aim is to establish sustainable businesses, build regional capability and stimulate the overall development of the sector.
Our first priority has been to address the region’s most pressing healthcare needs through the creation of specialist healthcare facilities. In collaboration with medical organizations such as Johns Hopkins Medicine International, Imperial College London and Cleveland Clinic, our goal is to create an integrated healthcare network, supported by state-of-the-art IT systems and medical technologies to provide excellent clinical outcomes and a seamless patient experience.
The Imperial College London Diabetes Centre is a state-of-the-art specialised out-patient one-stop facility that specialises in Diabetes Treatment, Training, Public Health and Research. Located in Abu Dhabi (next to the Zayed Military Hospital), ICLDC allows the highest level of specialised patient care, from first diagnosis to the continued management of all complications associated with Diabetes.
Imperial College London holds a renowned history and expertise in the study of Diabetes, bringing one of the leading medical academic institutions in the world to Abu Dhabi as a core working partner. Under ICLDC practices, one of the Centre’s primary objectives will be to provide continuing education for health professionals and the general public. For more details visit: http://www.icldc.ae
Edelman Public Relations
M: +971 (0)50 800 8268
Carol Sansour Dabdoub
Imperial College London Diabetes Centre
M: +971 509 726 507